| Prev Close | 281.62 |
| Open | 280.50 |
| Day Low/High | 280.50 / 287.28 |
| 52 Wk Low/High | 278.72 / 442.00 |
| Volume | 80.90K |
| Avg Volume | 757.00K |
Regeneron Pharmaceuticals Inc. (REGN)
285.32
3.70
1.30
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 107.98M |
| Market Cap | 31.23B |
| EPS | 22.60 |
| P/E Ratio | 15.49 |
| Div & Yield | N.A. (N.A) |
Latest News
Real Money Post-Industrial Average Leads Major Indexes So Far for Year
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
2 Well-Known Stocks You Should Consider Shorting This Week
These bearish bets are showing both technical and quantitative deterioration.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Real Money Post-Industrial Average Leaves Major Indices in the Dust
RMPIA outperformed once gain during April.
A Bullish Play on Netflix
Netflix is bullish, but faces key resistance before it can make a big run higher.
Stalking an Entry in Regeneron Pharmaceuticals
A low-risk countertrend options trade may be worth a look in this name.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative
So far 2019 is proving to be a year where things have a habit of working out right.
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
2 Well-Known Stocks to Consider Shorting Thanksgiving Week
These 'Bearish Bets' are showing both technical and quantitative deterioration.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
Regeneron Soars After My 'Go Long' Recommendation: What Now?
An updated strategy for the high-flying REGN.
Regeneron Is Leading the Way for Biotech
Recent action tells us REGN's momentum is super strong.
Jim Cramer: Move Over FANG, Long Live INJFANG
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
Aggressive Traders Must Go Long Regeneron Pharmaceuticals
We have more evidence to support the bull case.
Regeneron Downtrend Ending But No Rush to Buy
Stock still needs a period of base building to support advance.
12 Blue-Chip Bargains: Keep Calm and Hope for a Deeper Correction
Thanks to the stock market correction many world-class stocks are back down to attractive levels.
Jim Cramer: Stocks Are on Fire For Good Reasons
Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.
7 Hot Investing Bets to Make in Biotech
These favorite names in the volatile sector offer the potential for high rewards.
Regeneron Pharmaceuticals: Look but Don't Touch This Bruised Stock Just Yet
Traders and investors should stand aside until the situation with this biotech name offers a better entry point.
Investors Shun Biotech Stocks
The speed at which investors have bailed on this sector is alarming.
Biotech Stocks to Watch: Part 1
Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.
DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
